<div class="welcome-screen" id="welcomeScreen">
    <div class="welcome-banner">
        <h1 id="welcome-title">Welcome to the page on positive and negative symptoms!</h1>
        <p id="welcome-description">Explore this to get a grasp on psychiatric methodology.</p>
    </div>

    <div class="explanation-card">
        <h1>Positive vs. Negative Symptoms in Psychiatric Disorders</h1>
        
        <p>In psychiatric assessment, symptoms are broadly categorized as <b>positive</b> (additions to normal experience/behavior) or <b>negative</b> (subtractions from normal functioning). This distinction originated in schizophrenia research but applies to other disorders as well. Understanding this dichotomy is crucial for phenomenology, prognosis, and treatment planning.</p>
        
        <h2>Positive Symptoms</h2>
        <p><b>Positive symptoms</b> represent pathological excesses or distortions of normal functions. They are often more dramatic and recognizable, typically responding better to pharmacotherapy.</p>
        
        <h3>Characteristics of Positive Symptoms:</h3>
        <ol>
            <li><b>Hallucinations</b>: Perceptions without external stimulus (auditory most common in schizophrenia)</li>
            <li><b>Delusions</b>: Fixed false beliefs resistant to reason (persecutory, referential, grandiose, etc.)</li>
            <li><b>Disorganized speech</b> (derailment, incoherence, word salad)</li>
            <li><b>Grossly disorganized behavior</b> (agitation, bizarre actions)</li>
            <li><b>Catatonic behavior</b> (excitement, posturing, negativism)</li>
        </ol>
        
        <p><b>Neurobiology:</b> Primarily associated with <b>dopaminergic hyperactivity</b> in mesolimbic pathways and temporal lobe abnormalities.</p>
        
        <h2>Negative Symptoms</h2>
        <p><b>Negative symptoms</b> represent diminution or loss of normal functions. They are often more insidious and debilitating, typically less responsive to treatment.</p>
        
        <h3>Characteristics of Negative Symptoms:</h3>
        <ol>
            <li><b>Affective flattening</b>: Reduced emotional expression (facial, vocal, gestural)</li>
            <li><b>Alogia</b>: Poverty of speech (brief, empty replies)</li>
            <li><b>Avolition</b>: Lack of goal-directed behavior (hygiene, work, school)</li>
            <li><b>Anhedonia</b>: Inability to experience pleasure (social, physical)</li>
            <li><b>Asociality</b>: Lack of interest in social interactions</li>
            <li><b>Attentional impairment</b></li>
        </ol>
        
        <p><b>Neurobiology:</b> Associated with <b>dopaminergic hypoactivity</b> in mesocortical pathways, prefrontal cortex dysfunction, and structural brain changes.</p>
        
        <h2>Clinical Significance of the Distinction</h2>
        <ol>
            <li><b>Prognosis</b>: Negative symptoms predict poorer long-term outcomes</li>
            <li><b>Treatment response</b>: Positive symptoms respond better to antipsychotics</li>
            <li><b>Pathophysiology</b>: Different neural circuits involved</li>
            <li><b>Diagnostic specificity</b>: Negative symptoms persist during remission of positive symptoms</li>
        </ol>
        
        <div class="mnemonic">
            <b>Mnemonic: POSITIVE vs. NEGATIVE</b><br>
            <b>POSITIVE</b> = <b>P</b>resent (added phenomena), <b>O</b>vert, <b>S</b>alient, <b>I</b>mproves with meds, <b>T</b>ransient (in episodes), <b>I</b>mpressive to observers, <b>V</b>ivid, <b>E</b>pisodic<br>
            <b>NEGATIVE</b> = <b>N</b>ot present (lost functions), <b>E</b>nduring, <b>G</b>radual onset, <b>A</b>pathic, <b>T</b>reatment-resistant, <b>I</b>nsidious, <b>V</b>ague, <b>E</b>veryday dysfunction
        </div>
        
        <h2>Primary vs. Secondary Negative Symptoms</h2>
        <p>Important to distinguish because treatment implications differ:</p>
        <ol>
            <li><b>Primary</b>: Intrinsic to illness (core feature of schizophrenia)</li>
            <li><b>Secondary</b>: Result from other factors:
                <ol>
                    <li>Positive symptoms (e.g., social withdrawal due to paranoia)</li>
                    <li>Depression</li>
                    <li>Medication side effects (e.g., parkinsonism causing blunting)</li>
                    <li>Environmental deprivation (institutionalization)</li>
                </ol>
            </li>
        </ol>
        
        <img src="positive_vs_negative_symptoms_brain_regions.jpg" alt="Diagram showing mesolimbic pathway hyperactivity in positive symptoms vs. prefrontal cortex hypoactivity in negative symptoms">
    </div>

    <div class="question-card">
        <h1>Question 1</h1>
        <p>Which of the following is considered a negative symptom of schizophrenia?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Auditory hallucinations</li>
            <li data-answer="wrong">Delusions of persecution</li>
            <li data-answer="correct">Affective flattening</li>
            <li data-answer="wrong">Catatonic excitement</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 2</h1>
        <p>A patient with schizophrenia shows improved delusions after antipsychotic treatment but continues to have poor hygiene and limited speech. This persistent symptomatology most likely represents:</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Treatment-resistant positive symptoms</li>
            <li data-answer="correct">Primary negative symptoms</li>
            <li data-answer="wrong">Medication side effects</li>
            <li data-answer="wrong">Conversion symptoms</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Assessment of Negative Symptoms</h1>
        
        <p>Accurate assessment requires careful observation and specific tools, as negative symptoms are often subtle and may be confused with depression or medication effects.</p>
        
        <h2>Clinical Assessment Techniques</h2>
        <ol>
            <li><b>Observation of spontaneous behavior</b>:
                <ol>
                    <li>Facial expressivity during interview</li>
                    <li>Gestures and body language</li>
                    <li>Speech quantity and quality</li>
                </ol>
            </li>
            <li><b>Structured interviews</b>:
                <ol>
                    <li>Scale for Assessment of Negative Symptoms (SANS)</li>
                    <li>Positive and Negative Syndrome Scale (PANSS)</li>
                    <li>Brief Negative Symptom Scale (BNSS)</li>
                </ol>
            </li>
            <li><b>Collateral history</b>:
                <ol>
                    <li>Change from premorbid functioning</li>
                    <li>Daily activities and self-care</li>
                    <li>Social engagement patterns</li>
                </ol>
            </li>
        </ol>
        
        <h2>Differential Diagnosis of Negative Symptoms</h2>
        <ol>
            <li><b>Depression</b>:
                <ol>
                    <li>Dysphoric mood present</li>
                    <li>Diurnal variation common</li>
                    <li>Anhedonia may be more selective</li>
                </ol>
            </li>
            <li><b>Extrapyramidal side effects</b>:
                <ol>
                    <li>Correlates with medication timing</li>
                    <li>Improves with anticholinergics/dose reduction</li>
                </ol>
            </li>
            <li><b>Frontal lobe lesions</b>:
                <ol>
                    <li>Executive function deficits prominent</li>
                    <li>May have disinhibition features</li>
                </ol>
            </li>
        </ol>
        
        <div class="mnemonic">
            <b>Mnemonic: 5 A's of Negative Symptoms</b><br>
            <b>A</b>ffect (flat), <b>A</b>logia, <b>A</b>volition, <b>A</b>nhedonia, <b>A</b>ttention
        </div>
    </div>

    <div class="question-card">
        <h1>Question 3</h1>
        <p>Which assessment tool is specifically designed to evaluate negative symptoms?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Hamilton Rating Scale for Depression</li>
            <li data-answer="correct">Scale for Assessment of Negative Symptoms (SANS)</li>
            <li data-answer="wrong">Yale-Brown Obsessive Compulsive Scale</li>
            <li data-answer="wrong">Beck Anxiety Inventory</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 4</h1>
        <p>A patient on haloperidol develops slowed movements and emotional blunting. The most appropriate next step is to:</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Increase antipsychotic dose</li>
            <li data-answer="correct">Assess for extrapyramidal symptoms</li>
            <li data-answer="wrong">Add an antidepressant</li>
            <li data-answer="wrong">Discontinue all medications</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Treatment Approaches</h1>
        
        <h2>Positive Symptoms</h2>
        <ol>
            <li><b>Pharmacotherapy</b>:
                <ol>
                    <li>First-generation antipsychotics (D2 antagonists)</li>
                    <li>Second-generation antipsychotics (serotonin-dopamine antagonists)</li>
                    <li>Clozapine for treatment-resistant cases</li>
                </ol>
            </li>
            <li><b>Psychosocial interventions</b>:
                <ol>
                    <li>Cognitive-behavioral therapy for psychosis</li>
                    <li>Reality testing techniques</li>
                </ol>
            </li>
        </ol>
        
        <h2>Negative Symptoms</h2>
        <ol>
            <li><b>Pharmacotherapy</b> (limited efficacy):
                <ol>
                    <li>Second-generation antipsychotics preferred</li>
                    <li>Adjunctive antidepressants may help</li>
                    <li>Emerging agents targeting glutamatergic systems</li>
                </ol>
            </li>
            <li><b>Psychosocial interventions</b>:
                <ol>
                    <li>Social skills training</li>
                    <li>Cognitive remediation therapy</li>
                    <li>Supported employment programs</li>
                    <li>Behavioral activation</li>
                </ol>
            </li>
            <li><b>Address secondary causes</b>:
                <ol>
                    <li>Anticholinergics for drug-induced parkinsonism</li>
                    <li>Reduce high-dose antipsychotics when possible</li>
                </ol>
            </li>
        </ol>
        
        <img src="treatment_algorithm_positive_negative_symptoms.jpg" alt="Flowchart showing different treatment pathways for positive vs negative symptoms">
    </div>

    <div class="question-card">
        <h1>Question 5</h1>
        <p>Which of the following treatments shows the most efficacy for primary negative symptoms?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">High-potency first-generation antipsychotics</li>
            <li data-answer="wrong">Benzodiazepines</li>
            <li data-answer="correct">Social skills training combined with cognitive remediation</li>
            <li data-answer="wrong">Mood stabilizers</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 6</h1>
        <p>The superior efficacy of second-generation antipsychotics over first-generation agents is most clearly established for which symptom domain?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Positive symptoms</li>
            <li data-answer="wrong">Negative symptoms</li>
            <li data-answer="wrong">Cognitive symptoms</li>
            <li data-answer="correct">None of the above (no clear superiority)</li>
        </ul>
    </div>
    <div class="placeholder" id="empty">Test</div>

</div>